


HOSTED BY  
Contents lists available at ScienceDirect

## Asian Pacific Journal of Tropical Medicine

journal homepage: <http://ees.elsevier.com/apjtm>Original research <http://dx.doi.org/10.1016/j.apjtm.2016.04.016>**Chemical constituents, cytotoxic, antifungal and antimicrobial properties of *Centaurea diluta* Ait. subsp. *algeriensis* (Coss. & Dur.) Maire**Hanène Zater<sup>1,2,3</sup>, Joëlle Huet<sup>4</sup>, Véronique Fontaine<sup>5</sup>, Samir Benayache<sup>1</sup>, Caroline Stévigny<sup>3</sup>, Pierre Duez<sup>3,6\*</sup>, Fadila Benayache<sup>1\*</sup><sup>1</sup>Unité de recherche: Valorisation des Ressources Naturelles, Molécules Bioactives et Analyses Physicochimiques et Biologiques (VARENBIOMOL), Faculté des Sciences Exactes, Université Frères Mentouri Constantine 1, 25000 Constantine, Algeria<sup>2</sup>Université Ziane Achour, Cité du 5 Juillet, Route Moudjbara BP: 3117, 17000 Djelfa, Algeria<sup>3</sup>Laboratoire de Pharmacognosie, de Bromatologie et de Nutrition Humaine, Université Libre de Bruxelles (ULB), 1050 Bruxelles, Belgium<sup>4</sup>Laboratoire de Biopolymère et Nanomatériaux Supramoléculaire, Université Libre de Bruxelles (ULB), 1050 Bruxelles, Belgium<sup>5</sup>Unité de Microbiologie Pharmaceutique et Hygiène, Faculté de Pharmacie, Université Libre de Bruxelles (ULB), 1050 Bruxelles, Belgium<sup>6</sup>Service de Chimie Thérapeutique et de Pharmacognosie, Université de Mons (UMONS), 7000 Mons, Belgium**ARTICLE INFO****Article history:**

Received 15 Feb 2016

Received in revised form 16 Mar 2016

Accepted 8 Apr 2016

Available online 23 Apr 2016

**Keywords:**

Flavonoids

Lignans

*Centaurea diluta*

Asteraceae

Cytotoxic activity

**ABSTRACT**

**Objective:** To investigate the chemical composition of a moderately polar extract ( $\text{CHCl}_3$  soluble part of the  $\text{MeOH}-\text{H}_2\text{O}$  extract) obtained from the aerial parts (leaves and flowers) of *Centaurea diluta* Ait. subsp. *algeriensis* (Coss. & Dur.) Maire, a species endemic to Algeria and Morocco on which no reports are available to date. To evaluate *in vitro* the cytotoxic, antifungal and antimicrobial activities of this extract and the cytotoxic and antimicrobial activities of its isolated secondary metabolites.

**Methods:** The cytotoxic effects of the extract were investigated on 3 human cancer cell lines i.e. the A549 non-small-cell lung carcinoma (NSCLC), the MCF7 breast adenocarcinoma and the U373 glioblastoma using a MTT colorimetric assay. Biological data allowed to guide the fractionation of the extract by separation and purification on silica gel 60 (CC and TLC). The isolated compounds which were characterized by spectral analysis, mainly HR-ESIMS, HR-EIMS, UV and NMR experiments ( $^1\text{H}$ ,  $^{13}\text{C}$ , COSY, ROESY, HSQC and HMBC) and comparison of their spectroscopic data with those reported in the literature, were evaluated for cytotoxic activities on six cancer cell lines (A549, MCF7, U373, Hs683 human glioma, PC3 human prostate and B16-F10 murine melanoma). The direct and indirect antibacterial and antifungal activities were determined using microdilution methods for the raw extract and TLC-bioautography and micro-dilution methods against standard and clinical strains for the isolated compounds.

**Results:** The raw extract reduced cell viability with  $\text{IC}_{50}$ s of 27, 25 and 21  $\mu\text{g}/\text{mL}$  on A549, MCF7 and U373, respectively. Five secondary metabolites: two phenolic compounds (vanillin **1**, paridol **3**), a lignan [(-)-arctigenin **2**] and two flavonoid aglycones (eupatilin **4** and jaceosidin **5**), were then isolated from this extract. Moderate cytotoxic effects were observed for (-)-arctigenin **2** ( $\text{IC}_{50}$ : 28 and 33  $\mu\text{M}$  on Hs683 and B16-F10, respectively), eupatilin **4** ( $\text{IC}_{50}$ : 33 and 47  $\mu\text{M}$  on B16-F10 and PC3, respectively) and jaceosidin **5** ( $\text{IC}_{50}$ : 32 and 40  $\mu\text{M}$  on PC3 and B16-F10, respectively).

**Conclusions:** All the isolated compounds were described for the first time from this species. Although inactive against 7 tested microorganisms (fungi, bacteria and yeast, human or plant pathogens), the raw extract was able to potentiate the effect of beta-lactam

\*Corresponding authors. Pierre Duez, Laboratoire de Pharmacognosie, de Bromatologie et de Nutrition Humaine, Université Libre de Bruxelles (ULB), 1050 Bruxelles, Belgium; Fadila Benayache, Unité de recherche: Valorisation des Ressources Naturelles, Molécules Bioactives et Analyses Physicochimiques et Biologiques (VARENBIOMOL), Faculté des Sciences Exactes, Université Frères Mentouri Constantine 1, 25000 Constantine, Algeria.

Tel/Fax: +213 31 81 11 03

E-mails: [pierre.duez@umons.ac.be](mailto:pierre.duez@umons.ac.be), [fbenayache@yahoo.fr](mailto:fbenayache@yahoo.fr)

Peer review under responsibility of Hainan Medical College.

antibiotics on methicillin-resistant *Staphylococcus aureus* (MRSA), reducing the minimal inhibitory concentrations (MICs) by a factor of 2-32-fold. No synergy was found between the extract and streptomycin. From the five isolated compounds only jaseosidin **5** showed a moderate antimicrobial activity.

## 1. Introduction

The genus *Centaurea* (tribe Cynareae, family Asteraceae) is one of the most widely distributed plant genera in the world. *Centaurea* includes more than 500 species, 45 of which grow spontaneously in Algeria, with 7 species localized in the Sahara [1,2]. Although, to our best knowledge, no traditional uses or pharmacological studies are reported so far for the species *Centaurea diluta* (*C. diluta*), many other *Centaurea* species are well known in traditherapy. For example, in Turkey, dried flowers of *Centaurea cyanus* are used in infusion to relieve diarrhea, gain energy, increase appetite, and to relieve chest tightness; *Centaurea calcitrapa* is used (infusion) as a febrifuge; *Centaurea jacea* is used to reduce fever, to start menstruation, to relieve constipation and increase appetite [3,4]. In Tunisia, *Centaurea furfuracea*, an endemic species from the desert regions of the North of Africa [5], is used as astringent and diuretic [6], while, in Algeria, the roots of *Centaurea incana* are used in the area of Aurès for the treatment of liver diseases [7] and *Centaurea pullata* is used in the preparation of a local traditional dish called "El Hammama" [8]. Various studies have shown medicinal properties of *Centaurea* species, mainly as analgesic [9], cytotoxic [10], antibacterial [11] and antifungal [12].

*Centaurea* typically present high structural diversity in major bioactive compounds, including triterpenes, flavonoids, lignans and sesquiterpene lactones [13–21]. In specimens of *C. diluta*, cultivated in the botanical garden of Technical University of Braunschweig, Germany, polyacetylenic compounds have been reported [22–24]. In the essential oil of *C. diluta* Aiton aerial parts, collected from Sicily, Italy [25], the most abundant compounds were fatty acids and derivatives, notably hexadecanoic acid (21.3%) and (Z,Z)-9,12-octadecadienoic acid methyl ester (12.2%), followed by hydrocarbons (15.3%), terpenoids being present in low amounts (2.8%).

Given the interest of *Centaurea* pharmacology and phytochemistry, the present paper concentrates on a relatively unknown subspecies, *C. diluta* Ait. subsp. *algeriensis* (Coss. & Durieu) Maire [26], endemic to Algeria and Morocco [2].

## 2. Material and methods

### 2.1. Chemicals, reagents and general

Solvents were analytical grade. Trypsin 0.5% in EDTA, RPMI1640 red phenol and fetal bovine serum (FBS) were purchased from Gibco® Invitrogen (Merelbeke, Belgium). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was obtained from Sigma Aldrich® (Bornem, Belgium). Dimethyl sulfoxide (DMSO) was obtained from Merck® (Overijse, Belgium). RNase-free water was from Braun® (Machelen, Belgium). The Penicillin V was purchased from

Certa SA ACA Pharma NV, the ampicillin, amoxicillin and oxacillin were purchased from Sigma–Aldrich.

The absorbance of the reaction mixture of MTT test was measured by spectrophotometer microplate reader Model 680XR, Bio-Rad®, Nazareth Eke (Belgium). The cells were counted by Cells Culture Counter, Beckman (Analis®, Suarlée, Belgium). The following apparatus were also used: optical microscope PCM-type Axiovert S100 (Zeiss, Nederlands) and laminar flow hood class II (IKS®, Leerdam, Nederlands).

Melting points were determined on a SMP10 Büchi B-540 Stuart Biocote apparatus and are uncorrected. Plant material powdering: Mill: Culatti, CZ13 model, Reference DCFH48. TLC: pre-coated aluminum foil silica gel 60 F<sub>254</sub> & TLC silica gel 60 F<sub>254</sub> Plastic roll 500 × 20 cm (Merck KGaA, Germany), visualized using UV lamp (CAMAG 254 nm & 366 nm) and by detection with a spraying reagent (vanillin-sulfuric at 10% and/or anisaldehyde) followed by heating at 100 °C for 3–5 min. Column chromatography (CC): silica gel 60 (Merck KGaA, Germany, 230–400 mesh ASTM). Routine preparative thin-layer chromatography (PLC): silica gel plates (20 × 20 cm Silica gel 60 PF<sub>254</sub>, Merck), Optical rotation: Perkin–Elmer 241 polarimeter at  $\lambda_{\text{Na}}$  589 nm.

UV spectra were recorded using a Thermo Electron Corporation evolution 300 spectrophotometer. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on Bruker Avance 300, 400 MHz and Varian 600 MHz; 2D-NMR experiments (COSY, HSQC, HMBC, NOESY and ROESY) were performed on Bruker Avance 400 MHz or Varian 600 MHz spectrometers. Spectra of compounds **1**, **2** and **3** were recorded in CDCl<sub>3</sub>, compound **4** in DMSO-*d*<sub>6</sub> and compound **5** in CD<sub>3</sub>OD. A Shigemi tube was used for compound **2**.

High resolution mass spectra in positive mode were recorded by direct infusion using a 6520 series quadrupole time-of-flight (Q-TOF) mass spectrometer (Agilent, Palo Alto, CA, USA) fitted with an electrospray ionization (ESI) source in positive mode. The error between the observed and calculated masses is expressed in ppm; below 5 ppm, the compounds were considered to correspond to predicted formula.

### 2.2. Plant material

The aerial parts of *C. diluta* Ait. subsp. *algeriensis* (Coss. & Dur.) were collected in the flowering stage in the area of Djelfa (1 038 m, 34° 53' 39.6" N, 3° 3' 56.3" E) in June 2012. The plant was authenticated by Professor Mohamed Kaabache, specialist in the identification of Algerian *Centaurea* species (Ferhat Abbas University, Setif, Algeria). A voucher specimen has been deposited in the National Herbarium of Belgium (National Botanical Garden of Meise) under the number BR0000013666187.

### 2.3. Extraction and isolation

Air-dried aerial parts (leaves and flowers, 1.5 kg) of *C. diluta* Ait. subsp. *algeriensis* (Coss. & Dur.) were powdered (slight grinding with controlled temperature, up to 35 °C) and macerated at room temperature with MeOH–H<sub>2</sub>O (77:23, v/v) (25 L) for 48 h, four times. The filtrates were combined, concentrated under reduced pressure, diluted in H<sub>2</sub>O (600 mL) under magnetic stirring and maintained at 4 °C for one night to precipitate a maximum of chlorophylls. After filtration, the resulting solution was successively extracted with solvents with increasing polarities (petroleum ether, chloroform, ethyl acetate and *n*-butanol) [27,28]. The present study focused on the chloroform soluble part which was dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under vacuum at room temperature to yield the CHCl<sub>3</sub> extract (4.0 g, yield: 0.27%, w/w). The chloroform extract was fractionated by column chromatography (120 g of silica gel; CH<sub>2</sub>Cl<sub>2</sub>/EtOAc/MeOH step gradients) to yield 23 fractions (F<sub>1</sub>–F<sub>23</sub>), combined according to their TLC profiles.

Fraction F<sub>3</sub> (26.2 mg) (CH<sub>2</sub>Cl<sub>2</sub>/EtOAc 98:2) was subjected to preparative TLC on silica gel; eluting with petroleum ether/EtOAc/acetone (6:3:1) yielded vanillin **1** as white crystals (3.5 mg) [29,30].

Fractions F<sub>4</sub> (12.2 mg) (CH<sub>2</sub>Cl<sub>2</sub>/EtOAc 98:2), F<sub>5</sub> (13.0 mg) (CH<sub>2</sub>Cl<sub>2</sub>/EtOAc 98:2) and F<sub>6</sub> (28.5 mg) (CH<sub>2</sub>Cl<sub>2</sub>/EtOAc 95:5) were combined and rechromatographed by CC (600 mg of silica gel; cyclohexane/EtOAc/acetone step gradients) to yield 21 subfractions (F'<sub>1</sub>–F'<sub>21</sub>) according to TLC profiles. Subtraction F'<sub>3</sub> (cyclohexane/EtOAc/acetone 6:6:2) yielded (–)-arctigenin **2** (3.2 mg) [17,31] and subtraction F'<sub>4</sub> (cyclohexane/EtOAc/acetone 5:2.5:2.5) gave paridol **3** (4.5 mg) [32,33].

Fraction F<sub>8</sub> (CH<sub>2</sub>Cl<sub>2</sub>/EtOAc 95:5) (44.4 mg) yielded up on concentration a yellowish compound which was washed with MeOH to obtain eupatilin **4** (7.5 mg) as needles [11,34]. Fraction F<sub>10</sub> (CH<sub>2</sub>Cl<sub>2</sub>/EtOAc 87.5:12.5) (19.60 mg) was chromatographed on preparative plates of silica gel eluted with CH<sub>2</sub>Cl<sub>2</sub>/EtOAc (4:1) to give jaceosidin **5** as a yellowish powder (5.0 mg) [35,36].

### 2.4. Cell cultures

The human cancer cell lines included the A549 (Deutsche Sammlung von Mikroorganismen und Zellkulturen, DSMZ code ACC107), NSCLC carcinoma, the U373 (European Collection of Cell Culture, ECACC 08061901) glioblastoma, the PC3 prostate carcinoma (DSMZ code ACC465), the Hs683 glioma (American Type Culture Collection, ATCC code HTB-138) and the MCF7 (DSMZ code ACC115) breast adenocarcinoma. The murine tumor cell line included the B16-F10 (American Type Culture Collection ATCC code CRL-6475) melanoma.

#### 2.4.1. Viability assay

The cytotoxic properties of the raw chloroform extract and isolated compounds were assessed, using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [37,38]. Briefly, this test is based on the capability of living cells to reduce the yellow MTT to a blue formazan compound, a reaction mediated by the mitochondrial succinate dehydrogenase. Cells were seeded (cells per well, A549: 1500; B16F10: 1000; Hs683: 1500; MCF7: 2800; PC3:

3000; U373: 1800) and allowed to adhere for 24 h before adding test compounds (100 µL; final concentrations from 10<sup>–4</sup> M to 10<sup>–8</sup> M). In the same condition, for the chloroform extract, cells were seeded (cells per well, A549: 1200; MCF7: 2500; U373: 1800; 100 µL; final concentrations from 100 µg/mL to 10<sup>–2</sup> µg/mL). The cells in medium alone without drug were considered as a negative control. After 72 h contact, the culture medium was replaced by a 0.5 mg/mL MTT solution in RPMI medium without phenol red (100 µL/well). After 3 h incubation, the formazan crystals were centrifuged and dissolved in 100 µL/well of DMSO. The absorbance of each well was then measured at 570 nm and 690 nm (reference) wavelength. The IC<sub>50</sub> values were calculated as follows:

$$\text{IC}_{50} = [(X_2 - X_1) \times (50 - Y_1)/(Y_2 - Y_1)] + X_1, \text{ where.}$$

X<sub>1</sub> and X<sub>2</sub>: are the higher and lower concentrations that border the concentration that reduces the global cell growth by the value closest to 50%.

Y<sub>1</sub> and Y<sub>2</sub>: are the mean percentages of viable cells at the X<sub>1</sub> and X<sub>2</sub> concentrations.

### 2.5. Antimicrobial and antifungal assays

#### 2.5.1. Microorganisms

The microorganisms used in the antimicrobial tests were: (1) Gram-positive bacteria: *Staphylococcus aureus* ATCC 6538 (*S. aureus* ATCC 6538), *Staphylococcus aureus* C98506 (*S. aureus* C98506), *Staphylococcus aureus* C100459 (*S. aureus* C100459) and *Staphylococcus aureus* ATCC 33591 (*S. aureus* ATCC 33591); (2) Gram-negative bacteria: *Escherichia coli* ATCC 25922 (*E. coli* ATCC 25922) and a plant pathogen: *Pseudomonas syringae* DC 3000; (3) plant pathogen fungi: *Fusarium oxysporum*, *Fusarium oxysporum* sporulent, *Cladosporium cucumerinum*, *Botrytis cinerea*, *Colletotrichum lagenarium* and *Pythium aphanidermatum*; and (4) a plant pathogen yeast: *Rhodotorula aurantiaca*. The ATCC strains were obtained from the American Type Culture Collection; strains C98506 and C100459 were clinical isolates, a generous gift from the Centre Hospitalier Universitaire of Charleroi, Belgium (Mr. Lerson). Strains C98506, C100459 and ATCC 33591 are methicillin-resistant *Staphylococcus aureus* (MRSA). The different plant pathogens were provided by the Centre Wallon de Biologie Industrielle, Bio-Industrie Unité Gembloux Agro-Bio Tech, Université de Liège, 5030 Gembloux, Belgique (Dr. Ongena).

#### 2.5.2. Direct and indirect antimicrobial effects

Direct and indirect antibacterial effects were evaluated by a broth microdilution method [39].

The raw extract and isolated compounds, dissolved in DMSO, were further diluted in Mueller Hinton broth (MHB), the final DMSO concentration being maximum 4%. These solutions were transferred into 96-wells plates and serially diluted using MHB. The bacterial inoculum prepared from an overnight culture, diluted in 0.85% NaCl to achieve 0.5 Mc Farland (10<sup>8</sup> cells/mL), was further diluted 1/100 to be inoculated in the 96-wells plates (100 µL/well). The plates were incubated at 37 °C for 24 h, added with an aqueous solution of MTT (0.8 mg/mL) and reincubated for 4 h. The minimum inhibitory

concentrations (MIC) were the lowest concentrations that completely inhibited the growth of microorganisms, detected by unaided eyes using the MTT staining.

### 2.5.3. Direct and indirect antibacterial bioautography

TLC was performed for the extract and the purified compounds on precoated silica gel 60 F<sub>254</sub> glass plates (Merck, Darmstadt, Germany). Plates were thoroughly dried at room temperature. One mL of 0.5 Mc Farland microorganism suspension was added to 9 mL MH agar (10<sup>7</sup> CFU/mL) at 37 °C and poured on the TLC plates. After solidification, the plates were incubated overnight at 37 °C. The bioautography was subsequently visualized by spraying MTT (0.8 mg/mL) followed by an additional incubation at 37 °C for 4 h [40].

To study indirect antibacterial activity against MRSA, a sub-inhibitory concentration of penicillin V (1 µg/mL) was incorporated in the mixture of MHB and agar; products with no direct antibacterial activity were selected, chromatographed, and bioautographed with this medium as described above.

## 3. Results

### 3.1. Structural elucidation of compounds 1–5

The structures of the isolated compounds were established by spectral analysis, mainly UV–Vis, HRESI-MS, <sup>1</sup>H-, <sup>13</sup>C-, and 2D-NMR (COSY, ROESY, HSQC and HMBC) as well as by comparing their spectroscopic data with those reported in the literature.

**Vanillin 1:** White crystals; MP = 82 °C; UV (MeOH)  $\lambda_{\text{max}}(\text{nm})$ : 230, 279, 309; HRESI-QTOF-MS (positive mode)  $m/z$ : 153.0545 [M+H]<sup>+</sup> (calculated for C<sub>8</sub>H<sub>9</sub>O<sub>3</sub>: 153.0546), 175.0372 [M+Na]<sup>+</sup> (calculated for C<sub>8</sub>H<sub>8</sub>O<sub>3</sub>Na: 175.0366), 191.0216 [M+K]<sup>+</sup> (calculated for C<sub>8</sub>H<sub>8</sub>O<sub>3</sub>K: 191.0105), measured exact mass: 152.0471 (calculated for C<sub>8</sub>H<sub>8</sub>O<sub>3</sub>: 152.0473), molecular formula C<sub>8</sub>H<sub>8</sub>O<sub>3</sub>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ (ppm, J/Hz): 9.83 (1H, s, H-7), 7.44 (1H, d,  $J$  = 1.8 Hz, H-2), 7.41 (1H, dd,  $J$  = 9.0, 1.8 Hz, H-6), 7.03, (1H, d,  $J$  = 9.0 Hz, H-5), 6.62 (1H, brs, 4-OH), 3.98 (3H, s, OCH<sub>3</sub>-3); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ (ppm): 190.86 (C, C-7), 151.62 (C, C-4), 147.05 (C, C-3), 130.33 (C, C-1), 127.45 (CH, C-6), 114.04 (CH, C-5), 108.75 (CH, C-2), 56.40 (CH<sub>3</sub>, OCH<sub>3</sub>-3).

(–)-Arctigenin **2:** White powder; MP = 103 °C;  $[\alpha]_D^{20} = -17.27^\circ$  (EtOH, c, 0.145); HRESI-QTOF-MS (positive mode)  $m/z$ : 373.1655 [M+H]<sup>+</sup> (calculated for C<sub>21</sub>H<sub>25</sub>O<sub>6</sub>: 373.1646), 395.1478 [M+Na]<sup>+</sup> (calculated for C<sub>21</sub>H<sub>24</sub>O<sub>6</sub>Na: 395.1467), measured exact mass: 372.1569 (calculated for C<sub>21</sub>H<sub>24</sub>O<sub>6</sub>: 372.1577). These data led to the molecular formula C<sub>21</sub>H<sub>24</sub>O<sub>6</sub>; HRESI-QTOF-MS/MS:  $m/z$ : 355.1556 [M+H–H<sub>2</sub>O]<sup>+</sup> (C<sub>21</sub>H<sub>23</sub>O<sub>5</sub>) which confirm the presence of a hydroxyl group; <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>) δ (ppm, J/Hz): 6.80 (1H, d,  $J$  = 7.9 Hz, H-5'), 6.72 (1H, d,  $J$  = 8.1 Hz, H-5), 6.62 (1H, d,  $J$  = 1.7 Hz, H-2'), 6.59 (1H, dd,  $J$  = 7.9, 1.7 Hz, H-6'), 6.53 (1H, dd,  $J$  = 8.1, 1.7 Hz, H-6), 6.44 (1H, d,  $J$  = 1.7 Hz, H-2), 5.50 (1H, brs, 4'-OH), 4.12 (1H, dd,  $J$  = 9.0, 7.4 Hz, H-9 $\alpha$ ), 3.87 (1H, dd,  $J$  = 9.0, 7.6 Hz, H-9 $\beta$ ), 3.83 (3H, s, OCH<sub>3</sub>-3'), 3.80 (3H, s, OCH<sub>3</sub>-4), 3.79 (3H, s, OCH<sub>3</sub>-3), 2.92 (1H, dd,  $J$  = 14.1, 5.3 Hz, H-7'a), 2.89 (1H, dd,  $J$  = 14.1, 7.1 Hz, H-7'b), 2.61 (1H, dd,  $J$  = 14.7, 7.4 Hz, H-7a), 2.54 (1H, m, H-8'), 2.52 (1H, m\*, H-7b), 2.47 (1H, m, H-8); \*: partially overlapped by the signal of H-8'; <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) δ (ppm):

178.96 (C, C-9'), 149.24 (C, C-3), 148.05 (C, C-3'), 146.91 (C, C-4), 144.76 (C, C-4'), 130.65 (C, C-1), 129.72 (C, C-1'), 122.32 (CH, C-6'), 120.80 (CH, C-6), 114.31 (CH, C-5'), 111.97 (CH, C-2'), 111.71 (CH, C-2), 111.48 (CH, C-5), 71.53 (CH<sub>2</sub>, C-9), 56.12 (CH<sub>3</sub>, OCH<sub>3</sub>-4), 56.07 (CH<sub>3</sub>, OCH<sub>3</sub>-3'), 56.02 (CH<sub>3</sub>, OCH<sub>3</sub>-3), 46.82 (CH, C-8'), 41.14 (CH, C-8), 38.42 (CH<sub>2</sub>, C-7), 34.74 (CH<sub>2</sub>, C-7'). Our results which were confirmed by the analysis of the ROESY spectrum experiment complete the spectroscopic data previously reported for this molecule [31,41].

**Paridol 3:** White powder; MP = 128 °C; HRESI-QTOF-MS (positive mode)  $m/z$ : 153.0544 [M+H]<sup>+</sup> (calculated for C<sub>8</sub>H<sub>9</sub>O<sub>3</sub>: 153.0546), 175.0369 [M+Na]<sup>+</sup> (calculated for C<sub>8</sub>H<sub>8</sub>O<sub>3</sub>Na: 175.0369), 343.0543 [2M+K]<sup>+</sup> (calculated for C<sub>16</sub>H<sub>16</sub>O<sub>6</sub>K: 343.0546), measured exact mass: 152.0472, (calculated for C<sub>8</sub>H<sub>8</sub>O<sub>3</sub>: 152.0473), molecular formula C<sub>8</sub>H<sub>8</sub>O<sub>3</sub>.

HRESI-QTOF-MS/MS of [M+H]<sup>+</sup>: 153.0547 [M+H]<sup>+</sup>, 135.0239 [M+H–H<sub>2</sub>O]<sup>+</sup>, 121.0289 [M+H–CH<sub>3</sub>OH]<sup>+</sup>, these two last ions confirmed the presence of the hydroxyl and methoxyl groups in the molecule; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ (ppm, J/Hz): 7.95 (2H, d,  $J$  = 8.9 Hz, H-2 & H-6), 6.86 (2H, d,  $J$  = 8.9 Hz, H-3 & H-5), 5.98 (1H, brs, 4-OH), 3.88 (3H, s, OCH<sub>3</sub>-7); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 167.08 (C, C-7), 159.90 (C, C-4), 132.06 (CH, C-2 & C-6), 122.93 (C, C-1), 115.33 (CH, C-3 & C-5), 52.08 (CH<sub>3</sub>, OCH<sub>3</sub>-7).

**Eupatilin 4:** Yellow crystals; MP = 236 °C; UV (MeOH)  $\lambda_{\text{max}}(\text{nm})$ : 276, 340; +NaOH: 276, 320, 360 (with hypochromic effect); +AlCl<sub>3</sub>: 282, 368; +AlCl<sub>3</sub> + HCl: 283, 361; +NaOAc: 276, 366; +NaOAc + H<sub>3</sub>BO<sub>3</sub>: 276, 357; HRESI-QTOF-MS (positive mode)  $m/z$ : 345.0968 [M+H]<sup>+</sup> (calculated for C<sub>18</sub>H<sub>17</sub>O<sub>7</sub>: 345.0969), 367.0788 [M+Na]<sup>+</sup> (calculated for C<sub>18</sub>H<sub>16</sub>O<sub>7</sub>Na: 367.0788), 383.0537 [M+K]<sup>+</sup> (calculated for C<sub>18</sub>H<sub>16</sub>O<sub>7</sub>K: 383.0528), 689.1736 [2M+H]<sup>+</sup> (calculated for C<sub>36</sub>H<sub>33</sub>O<sub>14</sub>: 689.1865), 712.1717 [2M+Na]<sup>+</sup> (calculated for C<sub>36</sub>H<sub>32</sub>O<sub>14</sub>Na: 712.1718), 727.1077 [2M+K]<sup>+</sup> (calculated for C<sub>36</sub>H<sub>32</sub>O<sub>14</sub>K: 712.1424), measured exact mass: 344.0888 (calculated for C<sub>18</sub>H<sub>16</sub>O<sub>7</sub>: 344.0896), molecular formula C<sub>18</sub>H<sub>16</sub>O<sub>7</sub>; <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ (ppm, J/Hz): 13.04 (1H, s, OH-5), 7.68 (1H, dd,  $J$  = 8.5, 2.0 Hz, H-6'), 7.56 (1H, d,  $J$  = 2.0 Hz, H-2'), 7.13 (1H, d,  $J$  = 8.5 Hz, H-5'), 6.97 (1H, s, H-3), 6.64, (1H, s, H-8), 3.88 (3H, s, 3'-OCH<sub>3</sub>), 3.85, (3H, s, 4'-OCH<sub>3</sub>) 3.75, (3H, s, 6-OCH<sub>3</sub>); <sup>13</sup>C NMR (100 MHz, DMSO-d<sub>6</sub>) δ (ppm): 182.01 (C, C-4), 163.26 (C, C-2), 157.12 (C, C-7), 152.83 (C, C-5), 151.96 (C, C-9), 149.06 (C, C-4'), 148.84 (C, C-3'), 131.11 (C, C-6), 122.83 (C, C-1'), 120.10 (CH, C-6'), 111.55 (CH, C-5'), 109.26 (CH, C-2'), 104.22 (C, C-10), 103.36 (CH, C-3), 94.33 (CH, C-8), 59.97 (CH<sub>3</sub>, OCH<sub>3</sub>-6), 55.88 (CH<sub>3</sub>, OCH<sub>3</sub>-4'), 55.76 (CH<sub>3</sub>, OCH<sub>3</sub>-3').

**Jaceosidin 5:** Yellowish powder; MP = 237 °C, UV (MeOH)  $\lambda_{\text{max}}(\text{nm})$ : 276, 346; +NaOH: 276, 314, 360 (with hyperchromic effect); +AlCl<sub>3</sub>: 282, 368; +AlCl<sub>3</sub> + HCl: 283, 361; +NaOAc: 278, 366; +NaOAc + H<sub>3</sub>BO<sub>3</sub>: 276, 357; HRESI-QTOF-MS (positive mode)  $m/z$ : 331.0811 (calculated for C<sub>17</sub>H<sub>15</sub>O<sub>7</sub>: 331.0812), 353.0625 [M+Na]<sup>+</sup> (calculated for C<sub>17</sub>H<sub>14</sub>O<sub>7</sub>Na: 353.0632), 661.1542 [2M+H]<sup>+</sup> (calculated for C<sub>34</sub>H<sub>29</sub>O<sub>14</sub>: 661.1552), 683.1485 [2M+Na]<sup>+</sup> (calculated for C<sub>34</sub>H<sub>28</sub>O<sub>14</sub>Na: 683.1371), 701.0942 [2M+K]<sup>+</sup> (calculated for C<sub>34</sub>H<sub>28</sub>O<sub>14</sub>K: 701.1137), 991.2454 [3M+H]<sup>+</sup> (calculated for C<sub>51</sub>H<sub>43</sub>O<sub>21</sub>: 991.2291), measured exact mass: 330.0744, (calculated for C<sub>17</sub>H<sub>14</sub>O<sub>7</sub>: 330.0740), molecular formula C<sub>17</sub>H<sub>14</sub>O<sub>7</sub>; <sup>1</sup>H NMR

(400 MHz,  $\text{CH}_3\text{OH}$ -d<sub>4</sub>)  $\delta$  (ppm,  $J/\text{Hz}$ ): 7.52 (1H, dd,  $J = 8.5, 2.0 \text{ Hz}$ , H-6'), 7.50 (1H, d,  $J = 1.9 \text{ Hz}$ , H-2'), 7.48 (1H, d,  $J = 8.5 \text{ Hz}$ , H-5'), 6.94 (1H, s, H-8), 6.64 (1H, s, H-3), 3.96 (3H, s, OCH<sub>3</sub>-3'), 3.88 (3H, s, OCH<sub>3</sub>-6). <sup>13</sup>C NMR (75 MHz,  $\text{CH}_3\text{OH}$ -d<sub>4</sub>)  $\delta$  (ppm): 184.21 (C, C-4), 166.36 (C, C-2), 158.92 (C, C-7), 154.83 (C, C-5), 154.70 (C, C-9), 151.70 (C, C-4'), 149.44 (C, C-3'), 132.92 (C, C-6), 123.90 (C, C-1'), 121.64 (C, C-6'), 116.91 (CH, C-5'), 110.34 (CH, C-2'), 105.58 (C, C-10), 103.59 (CH, C-3), 95.65 (CH, C-8), 61.04 (CH<sub>3</sub>, OCH<sub>3</sub>-6), 56.50 (CH<sub>3</sub>, OCH<sub>3</sub>-3').

### 3.2. Biological activities

#### 3.2.1. Cytotoxic effects

The  $\text{CHCl}_3$  extract showed cell growth inhibitory activity against all 3 tested cell lines in the  $\mu\text{g}/\text{mL}$  range (Figure 1). These results are in agreement with previous data from an Algerian *Centaurea* species; the raw chloroformic extract of *Centaurea musimonum* (musimonum) Maire showed on KB cells, cytotoxic activity with growth inhibition of 89% at 10  $\mu\text{g}/\text{mL}$  and 26% at 1  $\mu\text{g}/\text{mL}$  [10].

The evaluation of the isolated compounds **1** to **5** indicated moderate growth inhibitory/cytotoxic activities for eupatilin **4**

(33–85  $\mu\text{M}$ ), jaceosidin **5** (32–49  $\mu\text{M}$ ), and (−)-arctigenin **2** (28–82  $\mu\text{M}$ ) (Figure 1).

Our results showed that the chloroformic extract displayed more significant cytotoxic effects on cancer cells A549, MCF7 and U373 than the isolated pure compounds. This could be attributed to the synergistic interactions, more especially as this extract contains flavonoids for which it is thought that they may have a role to play in increasing the biological activity of other compounds by synergistic or other mechanisms [42].

#### 3.2.2. Antifungal and antimicrobial activities

Although inactive against 7 tested microorganisms (fungi, bacteria and yeast, human or plant pathogens, Table 1), the raw extract was able to potentiate the effect of beta-lactam antibiotics on methicillin-resistant *S. aureus* (MRSA), reducing the minimal inhibitory concentrations (MICs) by a factor of 2–32-fold (Table 2). In a direct antibacterial TLC-bioautography assay, compound **5** (jaceosidin), showed the highest activity (Tables 3 and 4). This was further investigated in a direct antibacterial assay, but the activity was relatively quite low on Gram positive and negative bacteria (MIC of 200  $\mu\text{g}/\text{mL}$  on MRSA C98506, MRSA C100459, MRSA ATCC 33591, MSSA ATCC 6538, *E. coli* ATCC 25922).




Figure 1. Cytotoxic effects ( $\text{IC}_{50}$ ) of the chloroform extract and the isolated compounds on different tumor cell lines.

**Table 1**MIC of the chloroform extract ( $\mu\text{g/mL}$ ).

Microorganisms tested		MIC $\mu\text{g/mL}$
<i>Staphylococcus aureus</i> ATCC 6538	Gram+	2000
<i>Escherichia coli</i> ATCC 25922	Gram-	2000
<i>Pseudomonas syringae</i> DC 3000	Gram-	a
<i>Fusarium oxysporum</i>	Fungus	a
<i>Fusarium oxysporum</i> sporulent	Fungus	a
<i>Cladosporium cucumerinum</i>	Fungus	a
<i>Botrytis cinerea</i>	Fungus	a
<i>Colletotrichum lagenarium</i>	Fungus	a
<i>Rhodotorula aurantiaca</i>	Fungus	a

<sup>a</sup> No effect at 250  $\mu\text{g/mL}$ , the highest concentration tested for plant pathogens.

**Table 2**Impact of the chloroform extract (200  $\mu\text{g/mL}$ ) on the susceptibility of the MRSA towards various beta-lactam antibiotics.

Tested mixture	MIC of the antibiotic ( $\mu\text{g/mL}$ )	
	MRSA C98506	MRSA C100459
Penicillin V alone (with DMSO 4%)	16	8
Penicillin V + chloroform extract (200 $\mu\text{g/mL}$ )	8	2
Ampicillin alone (with DMSO 4%)	16	4
Ampicillin + chloroform extract (200 $\mu\text{g/mL}$ )	8	4
Amoxicillin alone (with DMSO 4%)	16	8
Amoxicillin + chloroform extract (200 $\mu\text{g/mL}$ )	4	8
Oxacillin alone (with DMSO 4%)	16	4
Oxacillin + chloroform extract (200 $\mu\text{g/mL}$ )	0.5	2

## 4. Discussion

### 4.1. Phytochemical investigation

We report in this work the isolation, purification and structural elucidation of chemical components of the chloroform soluble part of the MeOH–H<sub>2</sub>O (77%) extract obtained from the aerial parts (leaves and flowers) of *C. diluta* Ait. subsp. *algeriensis* (Coss. & Durieu) Maire (Asteraceae). No report is available so far on the phytochemistry of this species endemic to Algeria and Morocco. The present phytochemical investigation allowed the isolation of a lignan [(-)-arctigenin], flavonoids (eupatilin and jaceosidin) and phenols (vanillin and paridol). These results are in agreement with major studies reported on different *Centaurea* species [14,43–48].

### 4.2. Biological activities

#### 4.2.1. Cytotoxic effects

The raw extract and the isolated compounds were evaluated for cytotoxic activity. Moderate cytotoxic effects were observed for three compounds, (-)-arctigenin **2**, eupatilin **4** and jaceosidin **5**, with IC<sub>50</sub>s in the range 25–50  $\mu\text{g/mL}$ . These data are in agreement with previous studies. Indeed, arctigenin (unspecified stereoisomer) as tumor specific agent that showed cytotoxicity to lung cancer (A549), liver cancer (HepG2) and stomach cancer (KATO III) cells, but not cytotoxic to several normal cell lines [49]. Arctigenin specifically inhibited the proliferation of cancer cells, which might consequently lead to the induction of apoptosis and is cytotoxic for human hepatocellular carcinoma cell lines, the IC<sub>50</sub> values after 12 h, 24 h and 48 h of treatment were respectively 38.29, 1.99 and 0.24  $\mu\text{M}$  [50], the highest activity was demonstrated with IC<sub>50</sub> values of 0.73  $\mu\text{M}$  (HeLa), 3.47  $\mu\text{M}$  (MCF7) and 4.47  $\mu\text{M}$  (A431) [46]. Eupatilin reduces aortic smooth muscle cell proliferation and migration by inhibiting PI3K, MKK3/6, and MKK4 activities (IC<sub>50</sub>, in Hec1A and KLE cells was 82.2 and 85.5  $\mu\text{M}$ ) [51,52] and jaceosidin can induce G2/M cell

**Table 3**Antibacterial activity of the purified compounds (**1–5**) measured by a direct TLC-bioautography.

Compounds	Inhibition zone in mm MRSA C98546		Inhibition zone in mm MRSA C100459	
	Test 1	Test 2	Test 1	Test 2
Vanillin	<b>1</b>	4	4	0
(-)-Arctigenin	<b>2</b>	1.5	1.5	0
Paridol	<b>3</b>	2	2	0
Eupatilin	<b>4</b>	5	5	6
Jaceosidin	<b>5</b>	19	19	21

**Table 4**Antibacterial activity of eupatilin **4** and jaceosidin **5**, measured by a direct TLC-bioautography with different amounts spotted.

Compounds	Inhibition zone in mm MRSA C98546		Inhibition zone in mm MRSA C100459	
	Test 1	Test 2	Test 1	Test 2
Eupatilin	<b>4</b> (15 $\mu\text{g}$ )	7	8	22
Eupatilin	<b>4</b> (25 $\mu\text{g}$ )	6	8	17
Eupatilin	<b>4</b> (50 $\mu\text{g}$ )	8	9	20
Jaceosidin	<b>5</b> (15 $\mu\text{g}$ )	15	15	>21
Jaceosidin	<b>5</b> (25 $\mu\text{g}$ )	15	17	>21
Jaceosidin	<b>5</b> (50 $\mu\text{g}$ )	>21	>21	>21

cycle arrest by inactivating cdc25C-cdc2 via ATM-Chk1/2 activation [53].

#### 4.2.2. Antifungal and antimicrobial activities

The raw extract and the isolated secondary metabolites were evaluated for antimicrobial activity. Although the raw extract didn't show any antimicrobial effect on various bacteria or fungi, it could potentiate the effect of beta-lactam antibiotics on methicillin-resistant *S. aureus* (MRSA), reducing the minimal inhibitory concentrations (MICs) by a factor of 2-32-fold. Jaceosidin 5 showed a moderate antimicrobial activity (MIC of 200 µg/mL on MRSA C98506, MRSA C100459, MRSA ATCC 33591, MSSA ATCC 6538, *E. coli* ATCC 25922). This is in agreement with previous results [54]. Jaceosidin 5 had the greatest potency (MICs 16–32 µg/mL) against most *S. aureus* isolates [55].

The identification of five compounds, vanillin, (−)-arctigenin, paradol, eupatilin and jaceosidin, from the aerial parts (leaves and flowers) of *C. diluta* Ait. subsp. *algeriensis* (Coss. & Dur.) M. (Asteraceae) emphasized the possible relevance of this plant for Algerian traditional medicine and it is surprising that no report has been published so far on eventual ethnomedical uses of this species. This may be due to a low distribution of this species or to an eventual toxicity that could have discouraged its use in traditherapy; this warrants investigation. A promising effect on bacterial resistance needs to be further investigated to identify the compound(s) able to reverse bacterial beta-lactam resistance.

#### Conflict of interest statement

We declare that we have no conflict of interest.

#### Acknowledgments

We thank Algerian government for financial support, HCDS Djelfa for helping us in the process of exploration and the harvest of plant material, professor M. Kaabeche for the identification of the plant material and C. Delporte (Laboratoire de Chimie Pharmaceutique Organique, Faculté de Pharmacie, Université Libre de Bruxelles (ULB) for the mass spectrometry measurement.

We thank Professor V. Mathieu (Laboratoire de Cancérologie et Toxicologie, Université Libre de Bruxelles) for access to her laboratory and help in performing the cytotoxicity experiments, Dr. Ongena Marc for access to her laboratory (Centre Wallon de Biologie Industrielle, Bio-Industrie Unité Gembloux Agro-Bio Tech, Université de Liège, 5030 Gembloux, Belgique) and Dr. E. Gicquel and J. Vancautenberg for the measurement of the optical rotation (Institut Meurice – Service de Chimie Organique Haute Ecole Lucia de Brouckère Avenue Emile Gryzon, 11070 Bruxelles).

#### References

- [1] Ozenda P. *Flore du Sahara septentrional et central*. Paris: CNRS; 1958, p. 450-454.
- [2] Quezel P, Santa S. *Nouvelle flore d'Algérie et des régions désertiques méridionales*. Paris: Centre National de La Recherche Scientifique (CNRS); 1963, p. 1016-1032.
- [3] Arif R, Küpeli E, Ergun F. The biological activity of *Centaurea* L. species (Review). *GU J Sci* 2004; **17**(4): 149-164.
- [4] Baytop T. *Türkiye'de Bitkiler ile Tedavi (Geçmişte ve Bugün)*. İstanbul: Nobel Tip Kitabevleri; 1999, p. 316.
- [5] Alapetite GP. *Flore de la Tunisie*. Tunis: Imprimerie Officielle de la République Tunisienne; 1981, p. 1060.
- [6] Fakhfakh JA, Damak M. Sesquineolignans from the flowers of *Centaurea furfuracea*, Coss. et Dur. (Asteraceae). *Nat Prod Res* 2007; **21**(12): 1037-1041.
- [7] Acclinou P, Boukerb A, Bouquant J, Massiot G, Le Men-Olivier L. Plantes des Aures : constituants des racines de *Centaurea incana*. *Plant Med Phytother* 1982; **16**: 303-309.
- [8] Djeddi S, Karioti A, Sokovic M, Stojkovic D, Seridi R, Skaltsa H. Minor sesquiterpene lactones from *Centaurea pullata* and their antimicrobial activity. *J Nat Prod* 2007; **70**(11): 1796-1799.
- [9] Djeddi S, Argyropoulou C, Chatter R. Analgesic properties of secondary metabolites from Algerian *Centaurea pullata* and Greek *C. grisebachii* ssp. *grisebachii*. *J Appl Sci Res* 2012; **8**(6): 2876-2880.
- [10] Medjroubi K, Benayache F, Bermejo J. Sesquiterpene lactones from *Centaurea musimonum*. Antiplasmodial and cytotoxic activities. *Fitoterapia* 2005; **76**: 744-746.
- [11] Ciric A, Karioti A, Glamocilja J, Sokovic M, Skaltsa H. Antimicrobial activity of secondary metabolites isolated from *Centaurea spruneri* Boiss. & Heldr. *J Serb Chem Soc* 2011; **76**: 27-34.
- [12] Koukoulitsa C, Geromichalos GD, Skaltsa H. VolSurf analysis of pharmacokinetic properties for several antifungal sesquiterpene lactones isolated from Greek *Centaurea* sp. *J Comput Aid Mol Des* 2005; **19**(8): 617-623.
- [13] Seghiri R, Boumaza O, Mekkioui R, Benayache S, Mosset P, Quintana J, et al. A flavonoid with cytotoxic activity and other constituents from *Centaurea africana*. *Phytochem Lett* 2009; **2**: 114-118.
- [14] Kollé EH, León F, Benayache F, Estévez S, Quintana J, Estévez F, et al. Cytotoxic sesquiterpene lactones and other constituents from *Centaurea omphalotricha*. *J Braz Chem Soc* 2012; **23**(5): 977-983.
- [15] López-Rodríguez M, GarcíaV P, Zater H, Benayache S, Benayache F. Cynaratriol, a sesquiterpene lactone from *Centaurea musimonum*. *Acta Cryst* 2009; **E65**: o1867-o1868.
- [16] Shoeb M, MacManus SMM, Nahar L, Jaspars M, Celik S, Sarker SD, et al. Bioactivity of two Turkish endemic *Centaurea* species, and their major constituents. *Braz J Pharmacogn* 2007; **17**: 155-159.
- [17] Shoeb M, Jaspars M, MacManus S, Celik S, Kong-Thoo-Lin P, Sarker S. Bioactivity of the extracts and the isolation of lignans from *Centaurea dealbata*. *Ars Pharm* 2006; **47**(4): 315-322.
- [18] Shoeb M, MacManus SM, Kumarasamy Y, Jaspars M, Nahar L, Thoo-Lin PK, et al. Americanin, a bioactive dibenzylbutyrolactone lignan, from the seeds of *Centaurea americana*. *Phytochemistry* 2006; **67**(21): 2370-2375.
- [19] Demir S, Karaalp C, Bedir E. Unusual sesquiterpenes from *Centaurea athoa* DC. *Phytochem Lett* 2016; **15**: 245-250.
- [20] Aktumsek A, Zengin G, Guler GO, Cakmak YS, Duran A. Assessment of the antioxidant potential and fatty acid composition of four *Centaurea* L. taxa from Turkey. *Food Chem* 2013; **141**(1): 91-97.
- [21] Milošević Ifantis T, Solujić S, Pavlović-Muratspahić D, Skaltsa H. Secondary metabolites from the aerial parts of *Centaurea panonica* (Heuff.) Simonk. from Serbia and their chemotaxonomic importance. *Phytochemistry* 2013; **94**: 159-170.
- [22] Bohlmann F, Postulka S, Ruhnke J. Polyacetylenverbindungen, XXIV. Die Polyne der gattung *Centaurea* L. *Chem Ber* 1958; **91**: 1642-1656.
- [23] Bohlmann F, Rode KM, Zdero C. Polyacetylenverbindungen, CXVII. Neue polyne der gattung *Centaurea*. *Chem Ber* 1966; **99**: 3544-3551.
- [24] Bohlmann F, Wotschokowsky M, Laser J, Zdero C, Bach KD. Polyacetylenverbindungen, 15 1. Über die Biogenese von Tri- und Tetraacetylenverbindungen. *Chem Ber* 1968; **101**(6): 2056-2061.
- [25] Ben Jemia M, Senatore F, Bruno M, Bancheva S. Components from the essential oil of *Centaurea aeolica* Guss. and *C. diluta* Aiton from Sicily, Italy. *Rec Nat Prod* 2015; **9**: 580-585.
- [26] Jahandiez E, Maire R. Catalogue des plantes du Maroc. Tome III. Dicotylédones et Supplément aux volumes I et II. *Cat Pl Maroc* 1934; **3**: 813-814.

- [27] Boudjerda A, Zater H, Benayache S, Chalchat JC, Gonzalez-Platas J, Leon F, et al. A new guianolide and other constituents from *Achillea ligustica*. *Biochem Syst Ecol* 2008; **36**: 461-466.
- [28] Aliouche L, Zater H, Zama D, Bentamene A, Seghiri R, Mekkioui R, et al. Flavonoids of *Serratula cichoracea* and their antioxidant activity. *Chem Nat Compd* 2007; **43**(5): 618-619.
- [29] Wang YL, Huang W, Chen S, Chen SQ, Wang SF. Synthesis, structure and tyrosinase inhibition of natural phenols derivatives. *J Chin Pharm Sci* 2011; **20**(3): 235-244.
- [30] Mohamad Nasir MI, Mohamad Yusof N, Mohd Salleh N, Coswald SS, Sollehudin S. Separation of vanillin from oil palm empty fruit bunch lignin. *Clean* 2008; **36**(3): 287-291.
- [31] Aslan Ü, Öksüz S. Chemical constituents of *Centaurea cuneifolia*. *Turk J Chem* 1999; **23**: 15-20.
- [32] Gelbrich T, Braun DE, Ellern A, Griesser UJ. Four polymorphs of methylparaben: structural relationships and relative energy differences. *Cryst Growth Des* 2013; **13**: 1206-1217.
- [33] Sajan D, Joe H, Jayakumar VS, Zaleski J. Structural and electronic contributions to hyperpolarizability in methyl *p*-hydroxy benzoate. *J Mol Struct* 2006; **785**: 43-53.
- [34] Kitouni R, Benayache F, Benayache S. Flavonoids of the exudate of *Centaurea calcitrapa*. *Chem Nat Compd* 2015; **51**(4): 762-763.
- [35] Belkacem S, Belbache H, Boubekri C, Mosset P, Rached-Mosbah O, Marchioni E, et al. Chemical constituents from *Centaurea parviflora* Desf. *Res J Pharm Biol Chem Sci* 2014; **5**(3): 1275-1279.
- [36] Kubacek TM, Haggag EG, El-Toumy SA, Ahmed AA, El-Ashmawy IM, Youns MM. Biological activity and flavonoids from *Centaurea alexanderina* leaf extract. *J Pharm Res* 2012; **5**(6): 3352-3361.
- [37] Mathieu V, Wauthoz N, Lefranc F, Niemann H, Amighi K, Kiss R, et al. Cyclic versus hemi-bastardins pleiotropic anti-cancer effects: from apoptosis to anti-angiogenic and anti-migratory effects. *Molecules* 2013; **18**(3): 3543-3561.
- [38] Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods* 1983; **65**: 55-63.
- [39] Okusa PN, Stévigny C, Devleeschouwer M, Duez P. Direct and indirect antimicrobial effects and antioxidant activity of *Cordia gilletii* De Wild (Boraginaceae). *J Ethnopharmacol* 2007; **112**: 476-481.
- [40] Okusa PN, Stévigny C, Devleeschouwer M, Duez P. Optimization of the culture medium used for direct TLC-bioautography. Application to the detection of antimicrobial compounds from *Cordia gilletii* De Wild (Boraginaceae). *J Planar Chromatogr* 2010; **23**(4): 245-249.
- [41] Damak N, Ghorbel H, Bahroun A, Damak M, Mc Killip A, Simmonds M. Flavonoids of the exudate of *Centaurea calcitrapa*. *J Soc Chim Tunis* 2000; **4**: 653-658.
- [42] Williamson EM. Synergy and other interactions in phytomedicines. *Phytomedicine* 2001; **8**: 401-409.
- [43] Yaglioglu AS, Demirtas I, Goren N. Bioactivity-guided isolation of antiproliferative compounds from *Centaurea carduiformis* DC. *Phytochem Lett* 2014; **8**(5): 213-219.
- [44] Khammar A, Djeddi S. Pharmacological and biological properties of some *Centaurea* species. *Eur J Sci Res* 2012; **84**(3): 398-416.
- [45] Erol-Dayi Ö, Pekmez M, Bona M, Aras-Perk A, Arda N. Total phenolic contents, antioxidant activities and cytotoxicity of three *Centaurea* species: *C. calcitrappa* subsp. *calcitrappa*, *C. ptosimopappa* and *C. spicata*. *Free Rad Antiox* 2011; **1**(2): 32-36.
- [46] Csapi B, Hajdú Z, Zupkó I, Berényi Á, Forgo P, Szabó P, et al. Bioactivity-guided isolation of antiproliferative compounds from *Centaurea arenaria*. *Phytother Res* 2010; **24**: 1664-1669.
- [47] Karamenderes C, Khan S, Tekwani BL, Jacob MR, Khan IA. Antiprotozoal and antimicrobial activities of *Centaurea* species Growing in Turkey. *Pharm Biol* 2006; **44**(7): 534-539.
- [48] Sarker SD, Kumarasamy Y, Shoeb M, Celik S, Eucel E, Middleton M, et al. Antibacterial and antioxidant activities of three Turkish species of the genus *Centaurea*. *Orient Pharm Exp Med* 2005; **5**(3): 246-250.
- [49] Susanti S, Iwasaki H, Itokazu Y, Nago M, Taira N, Saitoh S, et al. Tumor specific cytotoxicity of arctigenin isolated from herbal plant *Arctium lappa* L. *J Nat Med* 2012; **66**: 614-621.
- [50] Lu Z, Cao S, Zhou H, Hua L, Zhang S, Cao J. Mechanism of Arctigenin-Induced specific cytotoxicity against human hepatocellular carcinoma cell lines: Hep G2 and SMMC7721. *PLoS One* 2015; **10**(5): e0125727.
- [51] Cho JH, Lee JG, Yang Y I, Kim JH, Ahn JH, Baek NI, et al. Eupatilin, a dietary flavonoid, induces G2/M cell cycle arrest in human endometrial cancer cells. *Food Chem Toxicol* 2011; **49**(8): 1737-1744.
- [52] Son JE, Lee E, Seo SG, Lee J, Kim JE, Kim J, et al. Eupatilin, a major flavonoid of *Artemisia*, attenuates aortic smooth muscle cell proliferation and migration by inhibiting PI3K, MKK3/6, and MKK4 activities. *Planta Med* 2013; **79**(12): 1009-1016.
- [53] Lee JG, Kim JH, Ahn JH, Lee KT, Baek NI, Choi JH. Jaceosidin, isolated from dietary mugwort (*Artemisia princeps*), induces G2/M cell cycle arrest by inactivating cdc25C- cdc2 via ATM-Chk1/2 activation. *Food Chem Toxicol* 2013; **55**: 214-221.
- [54] Song GC, Ryu SY, Kim YS, Lee JY, Choi JS, Ryu CM. Elicitation of induced resistance against *Pectobacterium carotovorum* and *Pseudomonas syringae* by specific individual compounds derived from native Korean plant species. *Molecules* 2013; **18**(10): 12877-12895.
- [55] Barnes EC, Kavanagh AM, Ramu S, Blaskovich MA, Cooper MA, Davis RA. Antibacterial serrulatane diterpenes from the Australian native plant *Eremophila microtheca*. *Phytochemistry* 2013; **93**: 162-169.